檢索結果 - S. Peter Eggleton
- Showing 1 - 2 results of 2
-
1
-
2
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>RAS</i> Wild-Type Metastatic Colorec... 由 Shukui Qin, Jin Li, Liwei Wang, Jianming Xu, Ying Cheng, Yuxian Bai, Wěi Li, Nong Xu, Lizhu Lin, Qiong Wu, Yunfeng Li, Jianwei Yang, Hongming Pan, Xuenong Ouyang, Wensheng Qiu, Kaichun Wu, Jianping Xiong, Guanghai Dai, Houjie Liang, Chunhong Hu, Jun Zhang, Min Tao, Qiang Yao, Junyuan Wang, Jiongjie Chen, S. Peter Eggleton, Tianshu Liu
出版 2018Artigo
相關主題
Clinical endpoint
Confidence interval
Hazard ratio
Internal medicine
Medicine
Oncology
Adverse effect
Cancer
Cetuximab
Clinical trial
Colorectal cancer
Concordance
Discontinuation
Disease
Environmental health
FOLFOX
Folinic acid
Immune system
Immunology
KRAS
Oxaliplatin
Population
Progressive disease
Randomized controlled trial
Regimen
Response Evaluation Criteria in Solid Tumors
Surrogate endpoint
Tolerability